Skip to main content

Table 4 Cox proportional hazards model of relative hazards of re-infection during 28 day follow-up (946 patients).

From: Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

Variable

Relative hazard

95%CI

p-value

p-value (trend)

  

lower

upper

  

unsupervised treatment

1.77

0.82

3.79

0.144

 

age group

    

<0.001

   15 years and above

1.00 [reference]

    

   5–14 years

4.05

1.10

14.94

0.036

 

   <5 years

8.44

2.71

26.27

<0.001

 

lumefantrine dose (mg/Kg)

    

0.003

   ≥80

1.00 [reference]

    

   65–79

7.50

0.95

59.12

0.056

 

   50–64

13.95

1.82

106.65

0.011

 

   <50

12.72

1.08

150.22

0.043

Â